Beximco Pharmaceuticals (LSE:BXP) Total Receivables: £27.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
70 GF Score
Price £0.53
GF Value £0.48
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Total Receivables?

Beximco Pharmaceuticals LSE:BXP 70 Total Receivables is £27.1 Mil as of Mar. 2026. GuruFocus rates LSE:BXP with a GF Score™ of 70/100 and a GF Value™ of £0.48 (Fairly Valued). The stock has 5 warning signs investors should review.

Beximco Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was £27.1 Mil.

Beximco Pharmaceuticals Total Receivables Related Terms

Beximco Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Total Receivables Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.39 20.60 23.52 24.48 23.85

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 23.85 25.50 28.81 27.08
LSE:BXP
70GF Score
Beximco Pharmaceuticals PLC LSE:BXP
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of £27.1 Mil mean?
Beximco Pharmaceuticals (LSE:BXP) has a Total Receivables of £27.1 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Total Receivables too high?
Beximco Pharmaceuticals' current Total Receivables is £27.1 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Total Receivables compare to ZTS and UTHR?
Beximco Pharmaceuticals' Total Receivables of £27.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Total Receivables is £27.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Fairly Valued. The stock's GF Value™ is £0.48, compared to a current price of £0.53 — trading 10.4% above its estimated fair value. The current Total Receivables is £27.1 Mil. Beximco Pharmaceuticals' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Total Receivables is £27.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.53 is trading 10.4% above its estimated GF Value™ of £0.48. GuruFocus considers Beximco Pharmaceuticals to be Fairly Valued.

Key valuation signals for LSE:BXP:

  • Total Receivables: £27.1 Mil
  • GF Value™: £0.48 vs. price of £0.53 (10.4% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
70GF Score

Get the complete analysis for LSE:BXP

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.53
Price
£0.48
GF Value